Independent overview of clinical studies on weight management medication. Peer-reviewed research, summarised in plain language. We report both the benefits and the risks.
This overview is informational and does not replace medical advice. Magistra is a technology platform — we do not provide medical recommendations. Always consult a doctor.
In less than 10 years, the science of weight management has radically changed. Here is the timeline of key breakthroughs.
2017
First injectable treatment approved for weight management
2021
Next-generation treatment approved — 15% weight loss achieved in trials
2022
Dual-action treatment enters trials — targets two receptors simultaneously
2023
Dual-action treatment approved — 20%+ weight loss in head-to-head trials
2025
Oral tablets enter market — no more injections needed. Triple-action agents in trials
2026-28
Triple-action agents expected to reach 25-30% weight loss. Gene therapy research begins
Peer-reviewed research from top scientific journals, summarised in plain language.
Head-to-head trial with 751 participants: tirzepatide produced 20.2% mean body weight loss vs 13.7% for semaglutide over 72 weeks. Both had manageable side effect profiles. Nausea occurred in 28% of tirzepatide and 24% of semaglutide users but usually resolved within 2-4 weeks.
Analysis of multiple studies spanning 40-120 weeks showed sustained weight loss and improved blood sugar control. Key finding: patients who continued treatment maintained results. Those who stopped typically regained 50-70% of lost weight within 1-2 years — similar to what happens when you stop any ongoing treatment.
Large-scale study identified both benefits (significant weight loss, improved heart health markers, reduced inflammation) and risks (inflammation of the pancreas in ~1% of users, kidney issues in rare cases). Conclusion: for most patients with obesity, the benefits clearly outweigh the risks — but only under proper medical supervision.
Real-world data (actual patients, not just trial participants) confirmed what clinical trials showed. In everyday practice: tirzepatide resulted in 17.8% weight loss, injectable treatments 13.1%, and oral treatments 11.4%. The most common reason patients stopped: stomach-related side effects (nausea, diarrhoea) — which are usually temporary.
This paper warns that weight management medications are so effective that unsupervised use poses serious risks: too-rapid weight loss, muscle mass reduction, disrupted eating patterns, and dehydration from persistent nausea. The solution is not to avoid these treatments — it is to always use them under medical guidance with gradual dose increases.
Found substantial clinical benefit but noted that branded pricing (€300-400/month) raises cost-effectiveness concerns for healthcare systems. Compounding and biosimilar alternatives may improve accessibility without compromising quality — as they use the same active pharmaceutical ingredients manufactured to the same pharmacopoeia standards.
Medical terms explained in plain language.
Problems with the stomach and intestines: nausea, diarrhoea, constipation, stomach pain. These are the most common side effects and usually improve after 2-4 weeks.
How well your body manages blood sugar levels. Good glycemic control means your blood sugar stays within a healthy range — important for preventing diabetes.
A number calculated from your weight and height. BMI 25-29.9 = overweight, BMI 30+ = obesity. It's not perfect (doesn't account for muscle), but it's the standard screening tool.
Inflammation of the pancreas (an organ behind your stomach). Symptoms: severe stomach pain that radiates to the back, nausea, vomiting. Rare (~1% of users) but serious — stop treatment and see a doctor immediately.
A 'dummy' treatment with no active ingredient, used in clinical trials to measure how much of the effect comes from the actual medication versus the expectation of being treated.
A substance that activates a specific receptor in your body. Weight management medications activate receptors that control appetite and blood sugar, telling your brain you're full.
When a licensed pharmacist makes a medication specifically for you, instead of using a mass-produced factory product. Uses the same pharmaceutical-grade ingredients, but customised to your dose.
The official quality standards for pharmaceutical ingredients in Europe. If a compounding pharmacy uses 'Ph. Eur. grade' ingredients, they meet the same quality standards as branded drug manufacturers.
The Dutch register for healthcare professionals (Beroepen in de Individuele Gezondheidszorg). If a pharmacist or doctor is BIG-registered, they are officially licensed to practice in the Netherlands. You can verify anyone at bigregister.nl.
The time it takes for half of the medication to leave your body. Weight management injectables typically have a half-life of about 1 week, which is why they're usually given as weekly injections.
They mimic a natural hormone (GLP-1) that your gut releases after eating. This hormone tells your brain you're full, slows stomach emptying so you feel satisfied longer, and helps regulate blood sugar. The medication simply amplifies a signal your body already uses.
Compounded medications use the same active pharmaceutical ingredient (API) manufactured to European Pharmacopoeia standards. However, they haven't gone through the same clinical trials as branded products. The active ingredient is identical; the difference is in the manufacturing scale (individual vs. factory) and regulatory pathway.
Studies show that most people regain 50-70% of lost weight within 1-2 years after stopping. This is not a failure of the medication — it's because obesity is a chronic condition, similar to how blood pressure returns when you stop blood pressure medication. The best long-term results come from combining medication with lasting lifestyle changes.
Honestly: yes, possibly. The longest clinical trials are about 2.5 years. We don't have 10-year or 20-year safety data yet. The data we do have is reassuring — no unexpected serious risks have emerged — but science requires honesty about what we don't yet know. This is why medical supervision is essential.
Branded manufacturers invest billions in clinical trials, regulatory approval, and marketing. They also hold patents that prevent competition. The result: €300-400/month per patient. Compounding pharmacies use the same active ingredient but without the brand markup, patent costs, or marketing budget — bringing the price down to €155/month or less.
The science is clear: personalised weight management works. But it must be safe and supervised. Magistra connects you with licensed pharmacies and independent doctors.
Last updated: April 2026. We update this overview as new studies are published.
Personalised weight management, doctor-guided